

Brief report

Acetylation of GATA-1 is required for chromatin occupancy

Janine M. Lamonica, Christopher R. Vakoc, and Gerd A. Blobel

All 3 hematopoietic GATA transcription factors, GATA-1, GATA-2, and GATA-3, are acetylated, although the *in vivo* role of this modification remains unclear. We examined the functions of an acetylation-defective mutant of GATA-1 in maturing erythroid cells. We found that removal of the acetylation sites in GATA-1 does not impair its nuclear localization, steady-

state protein levels, or its ability to bind naked GATA elements *in vitro*. However, chromatin immunoprecipitation (ChIP) experiments revealed that mutant GATA-1 was dramatically impaired in binding to all examined cellular target sites *in vivo*, including genes that are normally activated and repressed by GATA-1. Together, these results suggest that acetyla-

tion regulates chromatin occupancy of GATA-1. These findings point to a novel function for transcription factor acetylation, perhaps by facilitating protein interactions required for stable association with chromatin templates *in vivo*. (*Blood*. 2006;108:3736-3738)

© 2006 by The American Society of Hematology

Introduction

GATA transcription factors regulate distinct steps during the development of the hematopoietic system. GATA-1 is expressed in erythroid cells, megakaryocytes, mast cells, and eosinophil granulocytes where it controls cellular functions both by activating and repressing gene transcription.¹⁻³ GATA-1 contains 2 highly conserved zinc fingers. The C-terminal zinc finger mediates DNA binding to typical GATA elements (WGATAR). The N-terminal zinc finger stabilizes binding to DNA and is required for GATA-1 binding to more complex palindromic GATA sites.

GATA-1 undergoes multiple posttranslational modifications, including phosphorylation, sumoylation, and acetylation. Acetylation of GATA-1 by the acetyltransferases CBP and p300 occurs predominantly at clustered lysine residues that reside at the C-terminal tails of both zinc fingers. These clusters are conserved among human, mouse, chicken, and zebra fish GATA-1 and also among GATA-2 and GATA-3 of various species.⁴⁻⁷ Additional, less prominent acetylation sites have been observed.^{4,5,8} How acetylation regulates GATA-1 function is unclear. Although acetylation of chicken GATA-1 is reported to strongly increase its affinity for DNA *in vitro*,⁴ no effects on DNA binding were observed upon acetylation of mouse GATA-1.⁵ Although *in vitro* acetylation of zebra fish GATA-1 slightly stimulated DNA binding,⁸ this did not appear to involve the conserved lysines near the zinc fingers, implying that additional acetylation sites contribute to these effects. Similarly, acetylation of GATA-2 by p300 moderately increased DNA binding but required the presence of multiple lysines, including those distinct from the lysines next to the C-terminal zinc finger.⁶ These data suggest that acetylation of GATA-1 and GATA-2 might exert mild effects on DNA binding *in vitro* when multiple lysines are modified. These subtle effects, if any, on DNA binding are in stark contrast to the substantial effects of acetylation site mutations on GATA-1 activity in erythroid cells *in vivo*,⁵ suggesting that acetylation might serve functions other than

directly modulating the affinity of GATA-1 for DNA. Here, we show that acetylation of GATA-1 is dispensable for DNA binding *in vitro* but essential for binding to chromatin *in vivo*.

Materials and methods

Cell cultures and viral infections

G1E cells were cultured as described.⁹ Cells were exposed to 1 μ M tamoxifen where indicated.

Alanine substitutions were introduced at the acetylated lysine residues (underlined) of GATA-1 near the N-terminal zinc finger (RPKKRMI) and the C-terminal zinc finger (SGKGKKKRGS). GATA-1 fused to the ligand-binding domain of the estrogen receptor (GATA-1-ER) or an acetylation-defective mutant of GATA-1(NC)-ER were introduced into MIG-R1 containing an IRES element followed by the GFP gene. Cells were infected as described⁹ and selected for GFP expression by FACS.

ChIP assay

The chromatin immunoprecipitation (ChIP) assay was performed exactly as described¹⁰ and analyzed by real-time PCR on an ABI Prism 7000 or 7900 system (AME Bioscience, Foster City, CA). Antibodies included anti-GATA-1 (N6; Santa Cruz Biotechnology, Santa Cruz, CA); and anti-ER (Ab10; Lab Vision Neomarkers, Fremont, CA). All primer sequences are described in Document S1 (available at the *Blood* website; see the Supplemental Materials link at the top of the online article).

Additional methods

Gel mobility shift assays and indirect immunofluorescence microscopy were performed according to standard protocols.

Results and discussion

G1E erythroid cells that lack GATA-1 are arrested at the proerythroblast stage, but they mature upon activation of stably expressed

From the Division of Hematology, the Children's Hospital of Philadelphia, PA; and the University of Pennsylvania School of Medicine, Philadelphia.

Submitted July 5, 2006; accepted July 14, 2006. Prepublished online as *Blood* First Edition Paper, August 3, 2006; DOI 10.1182/blood-2006-07-032847.

The online version of this article contains a data supplement.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

© 2006 by The American Society of Hematology




Figure 1. Equal DNA binding by GATA-1-ER and acetylation defective GATA-1(NC)-ER. EMSA with an α -globin–derived GATA site with nuclear extracts from G1E cells expressing GATA-1-ER and GATA-1(NC)-ER. As control, extracts from mouse erythroleukemia (MEL) cells and parental G1E cells were included. Anti-GATA-1 antibodies were added where indicated.

GATA-1 fused to the ligand-binding domain of the estrogen receptor (GATA-1-ER).⁹ To generate a GATA-1 mutant that is defective for acetylation, we substituted the acetylated lysine residues near each of the 2 zinc fingers with alanines (GATA-1(NC)-ER). These mutations markedly reduce GATA-1 acetylation in vitro and in vivo.⁵ Constructs were introduced into G1E cells via a retroviral vector containing the GFP cDNA. GFP-positive pools of cells were found to contain similar amounts of GATA-1-ER and GATA-1(NC)-ER (Figure S1A), suggesting that both proteins have comparable stability. Results shown here derive from pools of cells although individual clones produced the same results (not shown).

Because the GATA-1 acetylation sites conform to nuclear localization sequences, we examined whether GATA-1(NC)-ER accumulates normally in the nucleus by immunofluorescence microscopy. GATA-1(NC)-ER and GATA-1-ER exhibited the same nuclear staining intensity with little cytoplasmic signal (Figure S1B). GATA-1(NC)-ER failed to induce maturation of G1E cells and did not induce or repress any of the examined target genes (Figure S2).

Parallel electrophoretic mobility shift assays (EMSAs) and ChIP experiments were performed to compare in vitro DNA binding and in vivo occupancy of GATA-1 constructs. When assayed by EMSA with the TGATAA element from the murine α -globin promoter, both GATA-1-ER and GATA-1(NC)-ER bound with equal avidity (Figure 1), consistent with our previous findings.⁵ To examine whether potential differences in binding affinity might be revealed in the context of select nucleotides flanking the core GATA sequence, we examined DNA binding to probes containing the sequences TGATAG, AGATAA, and AGATAG that are found at certain GATA-1 target genes. No differences in DNA binding were observed between GATA-1-ER and GATA-1(NC)-ER at any of these sites (Figure S3). The residues near the C-terminal zinc finger that are targeted for acetylation do not make direct contact with DNA¹¹ and fall outside the basic region that plays a role in discriminating between distinct GATA elements.¹² This might explain why mutation or acetylation of these residues has no effect on DNA binding.

In vivo occupancy of GATA-1 at its native targets was measured by quantitative ChIP with primers for the α -globin promoter. Although GATA-1-ER occupancy was high when compared with

controls, GATA-(NC)-ER was virtually undetectable (Figure 2). Similar results were obtained at several additional GATA-1 targets, including the β -major, *Fog1*, *Band3*, *Ahsp*, and *Eklf* genes, and HS3 of the LCR (Figure S4A-F). We also considered the possibility that the determinants for GATA-1 association with its targets might be different at genes that are silenced by GATA-1.^{13,14} Thus, we examined GATA-1 occupancy at GATA elements of the *Gata2* and *c-Kit* genes, both of which are repressed by GATA-1. Again, GATA-1(NC)-ER failed to bind to these genes (Figure S4G-H).

Negative ChIP experiments need to be viewed with caution because disparate crosslinking efficiencies or epitope exposure between wild-type and mutant GATA-1 constructs might account for differences in detectability. Thus, we performed ChIP experiments with antibodies against the ER portion of the GATA-1 fusion proteins and obtained the same results (Figure 2; Figure S4A-H).

Acetylation of transcription factors has been shown to influence DNA binding, nuclear localization, protein stability, and protein-protein interactions.¹⁵ The present work suggests that mutations at the acetylation sites disrupt stable association with chromatin. Note that other mutations in GATA-1 that do not affect the residues required for DNA binding also show diminished chromatin occupancy to some sites in vivo. These include mutations that impair binding to FOG-1^{13,14} and select deletions outside the zinc finger domain of GATA-1 (Kirby D. Johnson, Shin-II Kim, and Emery H. Bresnick, manuscript submitted). This suggests that protein-protein interactions are important to stabilize GATA-1 at its target sites perhaps through the formation of a stable enhanceosome-like structure.¹⁶ Disruption of any single protein interaction might destabilize the enhanceosome, leading to diminished association of GATA-1 with its target site in vivo. We speculate that acetylation of GATA-1 promotes its association with one or more proteins critical for enhanceosome stability. Candidate proteins for acetylation-dependent GATA-1 binding include chromatin-modifying enzymes such as CBP/p300, which contain an acetyl-lysine binding bromodomain.¹⁷ This might increase the stability of the GATA-1–chromatin interaction by linking it to other DNA-binding proteins. Alternatively, these interactions might increase access of GATA-1 to chromatinized targets by directly regulating the fluidity of chromatin.

Mutations of residues that included the acetylation sites near the C-terminal zinc finger of zebra fish GATA-1 reduced




Figure 2. GATA-1(NC)-ER fails to bind GATA-1 target genes in vivo. ChIP assay using anti-GATA-1 (α G-1) and anti-ER (α ER) antibodies and control rat and mouse IgG (rIG and mIG). Error bars indicate SD.

self-association and transcriptional activity.⁸ This finding was interpreted to suggest that self-association is required for GATA-1 activity *in vivo*. However, on the basis of the present work, it is possible that loss of chromatin occupancy caused the reported loss of GATA-1 activity. More generally, our findings emphasize that binding of transcription factors to naked DNA *in vitro* and chromatinized templates *in vivo* are functionally distinct and can be uncoupled by mutations.

Acknowledgments

We thank Mitchell Weiss and Emery Bresnick for critical comments on the manuscript.

References

1. Ferreira R, Ohneda K, Yamamoto M, Phillipsen S. GATA1 function, a paradigm for transcription factors in hematopoiesis. *Mol Cell Biol*. 2005;25:1215-1227.
2. Crispino JD. GATA1 in normal and malignant hematopoiesis. *Semin Cell Dev Biol*. 2005;16:137-147.
3. Lowry JA, Mackay JP. GATA-1: one protein, many partners. *Int J Biochem Cell Biol*. 2006;38:6-11.
4. Boyes J, Byfield P, Nakatani Y, Ogryzko V. Regulation of activity of the transcription factor GATA-1 by acetylation. *Nature*. 1998;396:594-598.
5. Hung H-L, Lau J, Weiss MJ, Blobel GA. CREB-binding protein (CBP) acetylates hematopoietic transcription factor GATA-1 at functionally important sites. *Mol Cell Biol*. 1999;19:3496-3505.
6. Hayakawa F, Towatari M, Ozawa Y, Tomita A, Privalsky ML, Saito H. Functional regulation of GATA-2 by acetylation. *J Leukoc Biol*. 2004;75:529-540.
7. Yamagata T, Mitani K, Oda H, et al. Acetylation of GATA-3 affects T-cell survival and homing to secondary lymphoid organs. *EMBO J*. 2000;19:4676-4687.
8. Nishikawa K, Kobayashi M, Masumi A, et al. Self-association of Gata1 enhances transcriptional activity *in vivo* in zebra fish embryos. *Mol Cell Biol*. 2003;23:8295-8305.
9. Weiss MJ, Yu C, Orkin SH. Erythroid-cell-specific properties of transcription factor GATA-1 revealed by phenotypic rescue of a gene targeted cell line. *Mol Cell Biol*. 1997;17:1642-1651.
10. Letting DL, Rakowski C, Weiss MJ, Blobel GA. Formation of a tissue-specific histone acetylation pattern by the hematopoietic transcription factor GATA-1. *Mol Cell Biol*. 2003;23:1334-1340.
11. Omichinski JG, Clore GM, Schaad O, et al. NMR structure of a specific DNA complex of Zn-containing DNA binding domain of GATA-1. *Science*. 1993;261:438-446.
12. Ghirlando R, Trainor CD. Determinants of GATA-1 binding to DNA: the role of non-finger residues. *J Biol Chem*. 2003;278:45620-45628.
13. Pal S, Cantor AB, Johnson KD, et al. Coregulator-dependent facilitation of chromatin occupancy by GATA-1. *Proc Natl Acad Sci U S A*. 2004;101:980-985.
14. Letting DL, Chen YY, Rakowski C, Reedy S, Blobel GA. Context-dependent regulation of GATA-1 by friend of GATA-1. *Proc Natl Acad Sci U S A*. 2004;101:476-481.
15. Kouzarides T. Acetylation: a regulatory modification to rival phosphorylation? *EMBO J*. 2000;19:1176-1179.
16. Carey M. The enhanceosome and transcriptional synergy. *Cell*. 1998;92:5-8.
17. Blobel GA, Nakajima T, Eckner R, Montminy M, Orkin SH. CREB-binding protein (CBP) cooperates with transcription factor GATA-1 and is required for erythroid differentiation. *Proc Natl Acad Sci U S A*. 1998;95:2061-2066.

This work was supported by National Institutes of Health grants DK58044 and DK54937 (G.A.B.).

Authorship

G.A.B., J.M.L., and C.R.V. designed the research and prepared the manuscript; and J.M.L. and C.R.V. performed the research.

The authors declare no competing financial interests.

J.M.L. and C.R.V. contributed equally to this study.

Correspondence: Gerd A. Blobel, Division of Hematology, The Children's Hospital of Philadelphia, Philadelphia, PA 19104; e-mail: blobel@email.chop.edu.